Aimmune Therapeutics
OverviewSuggest Edit
We are a clinical-stage biopharmaceutical company advancing a new therapeutic approach, including the development of proprietary product candidates, for the treatment of peanut and other food allergies. The Company's therapeutic approach, which it refers to as Characterized Oral Desensitization ImmunoTherapy, or CODITTM, is designed to desensitize patients to food allergens and thereby reduce the risk of having an allergic reaction upon accidental exposure, or reduce symptom severity should an allergic reaction occur. CODIT is intended to reduce meaningfully the burden and anxiety experienced by food-allergic patients and their families.
| Type | Public | |
| Founded | 2011 | |
| HQ | Brisbane, CA, US | Map |
| Website | aimmune.com | |
| Employee Ratings | More | |
| Overall Culture | A+ | More |
Recent NewsAll News
- North America Allergy Immunotherapies Market Is Set for a Rapid Growth and is Expected to Reach USD Billion by 2027 - Johnson and Johnson Services, Inc., Aimmune Therapeutics, Anergis, Circassia
- Aimmune Therapeutics, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit: Portnoy Law Firm
- Monteverde & Associates PC Files Class Action Lawsuit On Behalf Of Shareholders Of Aimmune Therapeutics, Inc. In The Northern District Of California
- Nestlé completes acquisition of Aimmune Therapeutics
Key People/Management at Aimmune Therapeutics
Andrew Oxtoby
President & Chief Executive Officer
Eric Bjerkholt
Chief Financial Officer
Samina Bari
Senior Vice President, Corporate Affairs
Fabiana Lacerca-Allen
Senior Vice President, Compliance
Cathy Nolan
Senior Vice President, Strategy, Marketing & Innovation
Douglas Sheehy
General Counsel and Secretary
Aimmune Therapeutics Office Locations
Aimmune Therapeutics has offices in Brisbane, Durham, München, Dublin and in 1 other location
Brisbane, CA, US (HQ)
8000 Marina Blvd #200
Durham, NC, US
1005 Slater Rd #300
München, DE
Mies-van-der-Rohe-Straße 6
Dublin, IE
Block B, The Crescent Building
London, GB
10 Eastbourne Terrace, Paddington
Aimmune Therapeutics Financials and Metrics
Aimmune Therapeutics Revenue
| USD | |
|---|---|
Net income (Q2, 2020) | (69.2m) |
EBIT (Q2, 2020) | (66.0m) |
Market capitalization (16-Oct-2020) | 2.3b |
Closing stock price (16-Oct-2020) | 34.5 |
Cash (30-Jun-2020) | 266.6m |
EV | 2.1b |
Aimmune Therapeutics's current market capitalization is $2.3 b.
Annual
Annual
Quarterly
| USD | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 58.5m | 112.7m | 65.0m | 74.4m | 76.9m | 78.7m | 84.5m | 73.8m | 209.3m | 142.2m | 78.4m | 81.1m | 72.6m | 76.8m | 298.4m | 266.6m |
Accounts Receivable | 772.0k | 25.0k | ||||||||||||||
Prepaid Expenses | 2.1m | 1.2m | 5.0m | 3.8m | 2.3m | 2.6m | 5.3m | 6.1m | 8.4m | 6.8m | 6.5m | 8.2m | 6.9m | 6.8m | 4.6m | 4.0m |
Inventories | 4.1m | 5.6m |
Annual
Quarterly
| USD | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | (10.8m) | (19.8m) | (15.5m) | (33.7m) | (55.7m) | (25.9m) | (58.4m) | (90.2m) | (49.5m) | (102.1m) | (153.8m) | (54.3m) | (117.1m) | (181.6m) | (86.4m) | (155.7m) |
Depreciation and Amortization | 30.0k | 60.0k | 125.0k | 257.0k | 393.0k | 144.0k | 387.0k | 703.0k | 356.0k | 738.0k | 1.1m | 666.0k | 1.8m | 2.9m | 1.3m | 2.7m |
Inventories | (4.0m) | (9.0m) | ||||||||||||||
Accounts Payable | (169.0k) | 536.0k | (78.0k) | (645.0k) | (393.0k) | 249.0k | 883.0k | 2.9m | (431.0k) | 2.6m | 8.1m | 1.9m | 5.5m | 4.3m | 191.0k | 1.4m |
| USD | Q2, 2015 |
|---|---|
Financial Leverage | 1.1 x |
Aimmune Therapeutics Cybersecurity Score
Aimmune Therapeutics Environment, Social & Governance (ESG) Ratings
Aimmune Therapeutics Online and Social Media Presence
1.56k Twitter followers
Aimmune Therapeutics has 1.56k Twitter Followers. The number of followers has decreased 0.7% month over month and decreased 1% quarter over quarter
Aimmune Therapeutics's Trends
Twitter Engagement Stats for @aimmune
691
Tweets
292
Following
1.6k
Followers
1
Tweets last 30 days
30
Avg. likes per Tweet
100%
Tweets with engagement
Aimmune Therapeutics Company Culture
Overall Culture
A+
90/100
CEO Rating
A+
85/100
Compensation
A+
92/100
Aimmune Therapeutics News and Updates
December 01, 2020
North America Allergy Immunotherapies Market Is Set for a Rapid Growth and is Expected to Reach USD Billion by 2027 - Johnson and Johnson Services, Inc., Aimmune Therapeutics, Anergis, Circassia
The North America allergy immunotherapies market was valued at US$ 697.53 million in 2019 and is projected to reach US$ 1,634.17 million by 2027; it is expected to grow at a CAGR of 11.3 % during the forecast period. Posted via Industry Today. Follow us on Twitter @IndustryToday
November 19, 2020
Aimmune Therapeutics, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit: Portnoy Law Firm
Investors with losses are encouraged to contact the firm before November 21, 2020; click here to submit trade information
October 15, 2020
Monteverde & Associates PC Files Class Action Lawsuit On Behalf Of Shareholders Of Aimmune Therapeutics, Inc. In The Northern District Of California
NEW YORK, Oct. 15, 2020 /PRNewswire/ -- Notice is hereby given that Monteverde & Associates PC has filed a class action lawsuit in the United States District Court for the Northern District of California, Case No. 4:20-cv-06733-YGR, on behalf of common shareholders of Aimmune...
October 13, 2020
Nestlé announces results of tender offer for Aimmune Therapeutics, Inc.
VEVEY, Switzerland, Oct. 13, 2020 /PRNewswire/ -- Société des Produits Nestlé S.A. ("Nestlé") today announced the results of the tender offer by its wholly-owned subsidiary, SPN MergerSub, Inc. ("Purchaser"), to purchase all of the outstanding shares ("Shares") of common stock of Aimmune...
September 19, 2020
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Aimmune Therapeutics, Inc. - AIMT
NEW YORK, Sept. 18, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating Aimmune Therapeutics, Inc. ("Aimmune" or the "Company") (AIMT)...
Aimmune Therapeutics Blogs
December 21, 2020
European Commission Approves Aimmune’s PALFORZIA® as First-Ever Treatment for Peanut Allergy in the EU
European Commission Approves Aimmune’s PALFORZIA® as First-Ever Treatment for Peanut Allergy in the EU
Content Import
Mon, 12/21/2020 - 01:15
European Commission Approves Aimmune’s PALFORZIA® as First-Ever Treatment for Peanut Allergy in the EU
December 21, 2020
…
October 14, 2020
Nestlé Completes Acquisition of Aimmune Therapeutics
Nestlé Completes Acquisition of Aimmune Therapeutics
Ram.Romen@west.com
Wed, 10/14/2020 - 01:53
Nestlé Completes Acquisition of Aimmune Therapeutics
October 14, 2020
This release is a backfill from a News Wire
General
Nestlé announced…
August 31, 2020
Aimmune Therapeutics Enters Definitive Agreement with Sociétés des Produits Nestlé S.A., Part of Nestlé Health Science
Aimmune Therapeutics Enters Definitive Agreement with Sociétés des Produits Nestlé S.A., Part of Nestlé Health Science
Content Import
Mon, 08/31/2020 - 01:15
Aimmune Therapeutics Enters Definitive Agreement with Sociétés des Produits Nestlé S.A., Part of Nestlé Health Science
…
August 24, 2020
Largest European Qualitative Study on Peanut Allergy Highlights Negative Impact of Avoidance and Fear of Accidental Peanut Allergy Reactions on Allergic Individuals and Their Caregivers
LONDON --(BUSINESS WIRE)--Aug. 24, 2020-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that findings from APPEAL-2 ( A llergy to P eanuts Im P acting E motions A nd L
August 07, 2020
Aimmune Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
Aimmune Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
Content Import
Fri, 08/07/2020 - 08:00
Aimmune Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
August 07, 2020
This release is a backfil…
July 30, 2020
Aimmune Therapeutics Announces Second Quarter 2020 Financial Results and Provides Recent Operational Highlights
PALFORZIA ® launch gaining momentum as allergist offices begin to re-open EU and Swiss regulatory reviews for PALFORZIA remain on schedule Enrollment in phase 3 POSEIDON trial has resumed $318 million cash, cash equivalents and investments Cost control measures limited second quarter EPS loss
Aimmune Therapeutics Frequently Asked Questions
When was Aimmune Therapeutics founded?
Aimmune Therapeutics was founded in 2011.
Who are Aimmune Therapeutics key executives?
Aimmune Therapeutics's key executives are Andrew Oxtoby, Eric Bjerkholt and Samina Bari.
How many employees does Aimmune Therapeutics have?
Aimmune Therapeutics has 275 employees.
Who are Aimmune Therapeutics competitors?
Competitors of Aimmune Therapeutics include Inovio Pharmaceuticals, Emisphere Technologies and Intercept Pharmaceuticals.
Where is Aimmune Therapeutics headquarters?
Aimmune Therapeutics headquarters is located at 8000 Marina Blvd #200, Brisbane.
Where are Aimmune Therapeutics offices?
Aimmune Therapeutics has offices in Brisbane, Durham, München, Dublin and in 1 other location.
How many offices does Aimmune Therapeutics have?
Aimmune Therapeutics has 5 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies